Literature DB >> 33514911

Oncology approvals in 2020: a year of firsts in the midst of a pandemic.

Laleh Amiri-Kordestani1, Richard Pazdur2,3.   

Abstract

Entities:  

Year:  2021        PMID: 33514911     DOI: 10.1038/s41571-021-00477-1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

Review 1.  The Globalization of Geriatric Oncology: From Data to Practice.

Authors:  Ravindran Kanesvaran; Supriya Mohile; Enrique Soto-Perez-de-Celis; Harpreet Singh
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-03
  1 in total
  3 in total

1.  FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.

Authors:  Nina Kim; Kelly J Norsworthy; Sriram Subramaniam; Haiyan Chen; Michael L Manning; Eliford Kitabi; Justin Earp; Lori A Ehrlich; Olanrewaju O Okusanya; Jonathon Vallejo; Brenda J Gehrke; R Angelo de Claro; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2022-08-15       Impact factor: 13.801

Review 2.  US Food and Drug Administration regulatory updates in neuro-oncology.

Authors:  Gautam U Mehta; Amy K Barone; Diana Bradford; Erin Larkins; Janice Kim; Lee Pai-Scherf; Adnan Jaigirdar; Mirat Shah; Suparna Wedam; Laleh Amiri-Kordestani; Marc R Theoret; Richard Pazdur; Julia A Beaver; Harpreet Singh
Journal:  J Neurooncol       Date:  2021-06-22       Impact factor: 4.130

Review 3.  Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining Progress.

Authors:  Donna R Rivera; Paul G Kluetz; Kald Abdallah; Sundeep Agrawal; Derek C Angus; Robert M Califf; Elizabeth Garrett-Mayer; Randall Hyer; Douglas R Lowy; Samir N Khleif
Journal:  Cancer J       Date:  2022 Mar-Apr 01       Impact factor: 2.074

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.